Knight Announces Normal Course Issuer Bid
MONTREAL, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Company"), a pan-American (ex-US) specialty pharmaceutical company, announced today acceptance by ...
How does the size and timing of this NCIB compare to recent buyback programs by peer companies in the specialty pharma sector?
What is the expected impact of the buyback on earnings per share (EPS) and valuation multiples?
How will the NCIB affect Knight Therapeutics' share liquidity and price volatility over the next 12 months?
21 days ago